NCT04106830 Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
| NCT ID | NCT04106830 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | NMO Spectrum Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2019-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2019-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases. Participants will receive magnetic resonance (MR) techniques including DIR, DKI, QSM, Rs-fMRI, conventional sequences (T1WI/T2WI/FLAIR), and the MR metabolic SPICE sequence, and will be followed up for one year using 3T MRI. In addition, participants will receive a one-time baseline examination including T1WI, T2WI, FLAIR, and SWI sequences on 7T MRI, as well as PET-MRI.
Eligibility Criteria
Inclusion Criteria: * 16-75 * Diagnosis of neuroinflammatory and demyelination disease * Availability of demographic and clinical data at the time disease onset * Informed written consent obtained from the patient, and/or patient's parent(s), and/or legal representative. Assent, if old enough to grant, will be obtained from all patients under the age of 16 years. Exclusion Criteria: * Patients for whom MRI is contra-indicated * Patients included in an ongoing clinical trial where the product is blinded
Contact & Investigator
Yaou Liu, PhD
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital
Frequently Asked Questions
Who can join the NCT04106830 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 75 Years, studying NMO Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04106830 currently recruiting?
Yes, NCT04106830 is actively recruiting participants. Contact the research team at yaouliu80@163.com for enrollment information.
Where is the NCT04106830 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04106830 clinical trial?
NCT04106830 is sponsored by Beijing Tiantan Hospital. The principal investigator is Yaou Liu, PhD at Beijing Tiantan Hospital. The trial plans to enroll 1,000 participants.